News for Aeterna Zentaris Inc. (AEZS.TO)

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories

**media[594187]**

TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) —

TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. ( CSCI) (TSX: CSCI) (”œCOSCIENS” or the ”œCompany”), a life science company

TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) —

**media[565509]**

TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) —

TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty...

“Cancer Cachexia Market” from 2024-2034 with covered segments By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), By Mechanism...

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) —

TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (

Aeterna Zentaris Completes Key DETECT-Trial Phase

OPENING CALL Stock futures pointed to minor losses on Monday as investors await a decision on interest rates from the Federal Reserve this week and the latest data on inflation. In Europe,...

TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX…

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) —

TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) —

Audited Consolidated Financial Statements of Ceapro Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 A-2 ...